<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02827643</url>
  </required_header>
  <id_info>
    <org_study_id>ID 01-59-11 ว</org_study_id>
    <nct_id>NCT02827643</nct_id>
  </id_info>
  <brief_title>Vitamin D and Calcium Supplement Attenuate Bone Loss Among HIV- Infected Patients Receiving Tenofovir Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz</brief_title>
  <official_title>Vitamin D and Calcium Supplement Attenuate Bone Loss Among HIV- Infected Patients Receiving Tenofovir Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz: An Open-label, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether calcium and vitamin D supplement can
      attenuate bone loss in HIV-infected-patients in Thailand who receive Tenofovir disoproxil
      fumarate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early initiation of antiretroviral therapy (ART) has transformed HIV infection into chronic
      manageable disease. Although incidence of AIDS-related mortality has decreased, it has
      increased for other co-morbid conditions including decrease bone mass, osteoporosis,
      fragility fracture. There are multi-factorial that contribute to bone loss in HIV-infected
      individuals including HIV virus itself that shift bone remodeling pathway toward bone
      resorption, lifestyle and behavioral factors, co-morbid conditions and ART.

      Initiation of ART is associated with 2%-6% reduction in bone mineral density during the first
      2 years of treatment regardless of ART regimens and then stabilization thereafter in the
      majority of the study. This magnitude of bone loss is similar to postmenopausal women during
      the first year.

      Tenofovir disoproxil fumarate (TDF) is a nucleotide analogue reverse transcriptase inhibitor,
      has been associated with greater bone loss than other reverse transcriptase inhibitors, that
      is recommended as the first line treatment in Thailand. Nonetheless there is an evidence in
      western country that calcium and vitamin D supplement can attenuate bone loss in naive
      HIV-infected individual who start ART with TDF. Even though many experts recommend to avoid
      TDF and prefer abacavir, NRTIs which affect bone loss less than other NRTIs, in high fracture
      risk patients, more than less HIV-infected-patients can access to abacavir in resource
      limiting country. This research aims to study bone mineral density (BMD) in HIV
      infected-patient in Thai population who receive tenofovir with calcium and vitamin D
      supplement.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage change of bone density</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in 25(OH)D level</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Bone Density</condition>
  <arm_group>
    <arm_group_label>TDF/3TC or FTC/EFV plus Calcium and vitamin D supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily calcium carbonate 1,250 mg that equal to elemental calcium 600 mg and weekly vitamin D2 20,000international units are given in intervention arms for duration of 24 weeks the subjects in this arm continue previous ART before enrollment to the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDF/3TC or FTC/EFV</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>the subjects in this arm continue previous ART before enrollment to study without any intervention with standard for HIV-infected patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TDF/3TC or FTC/EFV plus Calcium and vitamin D supplement</intervention_name>
    <description>Once daily calcium carbonate 1,250 mg that equal to elemental calcium 600 mg and weekly vitamin D2 20,000international units are given in intervention arms for duration of 24 weeks the subjects in this arm continue previous ART before enrollment to the study</description>
    <arm_group_label>TDF/3TC or FTC/EFV plus Calcium and vitamin D supplement</arm_group_label>
    <other_name>ergocalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TDF/3TC or FTC/EFV</intervention_name>
    <description>arm continue previous ART before enrollment to study without any intervention with standard for HIV-infected patient.</description>
    <arm_group_label>TDF/3TC or FTC/EFV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1-infected patients who start 3TC or FTC,TDF and EFV within 3 months before
             enrollment

          -  Age 18-50 years

        Exclusion Criteria:

          -  CrCl &lt;60mL/min/1.73 m2 ¶-

          -  CaCO3 supplement &gt;500 mg/day or vitamin D supplement &gt;800 IU/day

          -  Steroid used (equivalent to prednisolone&gt; 5 mg/day more than 3 months )

          -  Osteoporosis treatment

          -  Serum Ca &gt;10.5 g/dL

          -  History fragility fracture

          -  Pregnancy or breastfeeding

          -  Secondary amenorrhea

          -  Hyperthyroidism

          -  History of kidney stone

          -  Current active opportunistic infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patawee Boontanondha, M.D.</last_name>
    <phone>669-1774-6012</phone>
    <email>pataweeb44@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sasisopin Kiertiburanakul, M.D.MHS</last_name>
    <phone>662-201-0033</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Patawee Boontanondha</name>
      <address>
        <city>Faculty of Medicine Ramathibodi Hospital, Mahidol University</city>
        <state>Bangkok</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patawee Boontanondha, M.D.</last_name>
      <phone>669-1774-6012</phone>
      <email>pataweeb44@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Sasisopin Sasisopin Kiertiburanakul, MD, MHS</last_name>
      <phone>662-201-0033</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2016</study_first_submitted>
  <study_first_submitted_qc>July 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>July 7, 2016</last_update_submitted>
  <last_update_submitted_qc>July 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

